This clinical trial is focused on studying the effects of a new treatment called volrustomig in women with locally advanced cervical cancer. Cervical cancer is a type of cancer that occurs in the cells of the cervix, which is the lower part of the uterus that connects to the vagina. The study aims to determine if volrustomig is safe and effective for patients who have not shown disease progression after receiving a combination of chemotherapy and radiation therapy, known as chemoradiation.

Volrustomig, also known by its code name MEDI5752, is a type of medication called a monoclonal antibody. It is designed to target specific proteins in the body that may help the immune system fight cancer cells. In this study, volrustomig will be compared to a placebo to see if it can improve outcomes for patients. The study will also involve other medications such as Mycofit and Remsima, which are used in different contexts within the trial. Mycofit contains the active substance mycophenolate mofetil, and Remsima contains infliximab.

Participants in the trial will receive either volrustomig or a placebo through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants over time to assess the progression of the cancer and overall survival rates. The goal is to see if volrustomig can help delay the progression of the disease and improve the quality of life for those affected by locally advanced cervical cancer. The trial is expected to continue until 2029, with recruitment starting in 2024.